GSK plc(GSK)
GBX --+0.00%
Reward53Moderate
Risk17Low
75%Data
3.7% dividend yield
GSK
+0.0 · +0.00%
GBX · LSE
GSK plc | Healthcare
Defensive Anchor
Market Cap:72.80Bn
ⓘ
Reward Rating
53
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
17
Low
Risk Assessment
1 metric flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on GSK to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for GSK, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 2161p.

What is GSK plc?

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.

GSK · Verdict

Moderate reward · low risk

GSK stands out on volatility and profitability, but watch the growth signal.

Based on 88% data coverage

GSK · Verdict

What’s working & what to watch

Strengths 3

  • Volatility95/100

    Top decile vs peers

  • Profitability88/100

    17% net margin · 33% ROE

  • Cash flow87/100

    18% free-cash-flow margin

Watchouts 1

  • Growth34/100

    Rev +3.7% CAGR · earnings -27.4%

Model-based scoring. For information only — not financial advice.

What is GSK plc?

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 72.80B, and a P/E ratio of 15.4x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: Moderate (53)

The scoring profile indicates limited reward potential at this time, with profitability and valuation offering the most support. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
IndustryDrug Manufacturers - General
Market Cap72.80B
P/E Ratio15.4025
Dividend Yield3.66%
Beta0.295
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.